The estimated Net Worth of Edward M Basile is at least $3.5 Milión dollars as of 6 August 2024. Mr. Basile owns over 6,750 units of TransMedics stock worth over $1,075,986 and over the last 6 years he sold TMDX stock worth over $2,383,868. In addition, he makes $39,167 as Independent Director at TransMedics.
Sign up
Mr. Basile TMDX stock SEC Form 4 insiders trading
Edward has made over 7 trades of the TransMedics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 6,750 units of TMDX stock worth $189,810 on 6 August 2024.
The largest trade he's ever made was buying 8,500 units of TransMedics stock on 6 May 2019 worth over $136,000. On average, Edward trades about 3,271 units every 160 days since 2019. As of 6 August 2024 he still owns at least 7,482 units of TransMedics stock.
You can see the complete history of Mr. Basile stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edward Basile biography
Edward M. Basile serves as Independent Director of the Company. He is currently retired. During his 25 year tenure with the law firm King & Spalding, Mr. Basile served as Chair of the firm’s FDA and Life Sciences Practice and on the firm’s Policy and Compensation Committees. Mr. Basile’s law practice included representing large, medium and small medical device, pharmaceutical, and biotechnology companies before the U.S. Food and Drug Administration. Mr. Basile also served in the Chief Counsel’s Office of FDA as Associate Chief Counsel for Drugs & Biologics and Associate Chief Counsel for Enforcement from 1975 to 1985. Mr. Basile received a BSME from Lafayette College and a JD from George Washington University Law School. Basile’s decades of experience representing medical device, pharmaceutical and biotechnology companies qualify him to serve on our board of directors.
What is the salary of Edward Basile?
As the Independent Director of TransMedics, the total compensation of Edward Basile at TransMedics is $39,167. There are 9 executives at TransMedics getting paid more, with Waleed Hassanein having the highest compensation of $3,159,300.
How old is Edward Basile?
Edward Basile is 72, he's been the Independent Director of TransMedics since 2016. There are 1 older and 15 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.
What's Edward Basile's mailing address?
Edward's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.
Insiders trading at TransMedics
Over the last 6 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein a James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.
What does TransMedics do?
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
What does TransMedics's logo look like?
Complete history of Mr. Basile stock trades at TransMedics
TransMedics executives and stock owners
TransMedics executives and other stock owners filed with the SEC include:
-
Waleed Hassanein,
President, Chief Executive Officer, Director -
Tamer Khayal,
Chief Commercial Officer -
Dr. Waleed H. Hassanein,
Founder, MD, CEO, Pres & Director -
Dr. Tamer I. Khayal,
Chief Commercial Officer -
Stephen Gordon,
CFO. Treasurer & Sec. -
Stephen Gordon,
Chief Financial Officer, Treasurer, Secretary -
David Weill,
Independent Director -
James Tobin,
Independent Chairman of the Board -
Thomas Gunderson,
Independent Director -
Edward Basile,
Independent Director -
Edwin Kania,
Independent Director -
John Sullivan,
Vice President - Quality and Engineering -
Miriam Provost,
Vice President - Global Regulatory Affairs -
Laura Damme,
Vice President - Clinical Affairs -
John Carey,
Vice President - Operations -
Susan Goodman,
VP of HR -
Mark Anderson,
Sr. Director of Technology Devel. -
Ike Okonkwo,
VP of Fin. & Accounting -
John F. Carey,
VP of Operations -
Therapeutics Corp Lung Biot...,
-
Ventures Fund Iv General Pa...,
-
Capital Management, L.P.Abr...,
-
Merilee Raines,
-
Capital Management, L.P.Abr...,
-
Rakesh P. Godhani,
Chief Digital Officer -
Nicholas Corcoran,
See Remarks -
Stephanie Lovell,
-
Anil P. Ranganath,
See remarks